You can buy or sell Aptorum Group and other stocks, options, ETFs, and crypto commission-free!
Aptorum Group Limited Class A Ordinary Shares, also called Aptorum Group, is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. Read More The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
52 Week High
52 Week Low
Yahoo FinanceMay 7
What Percentage Of Aptorum Group Limited (NASDAQ:APM) Shares Do Insiders Own?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Aptorum Group Limited (NASDAQ:APM) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me wha...
Yahoo FinanceApr 30
UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on Aptorum Group Limited (APM) Click here to view Full Argus Report Highlights, as conveyed by Argus Analyst Steve Silver, include: COMPANY HIGHLIGHTS APM: Addressing Orphan Indications and Unmet Needs In our view, Aptorum has compiled an impressive pipeline of early-stage assets that we expect to drive significant value, both from internal development and...